Recent IPO activity remains robust into October 2026, with multiple U.S. listings scheduled this week—including TRex Bio and Retension Pharmaceuticals—and additional filings from biotech and AI infrastructure names such as Iambic Therapeutics. Broader 2026 volume has exceeded 250 deals year-to-date, supported by equity market gains and selective demand for growth stories, though several high-profile candidates have faced delays amid elevated valuations and bond-yield sensitivity. Trader focus centers on whether names like Anthropic can complete marketing and pricing before year-end, versus OpenAI and others shifting timelines into 2027. Key near-term catalysts include FOMC communications on rates, upcoming earnings that could influence risk appetite, and any new S-1 filings or confidential submissions that clarify deal pipelines. Market-implied odds reflect this mix of visible small-to-mid-size flow against execution risks for larger offerings.